ASX (ASXFF) Gets a Hold from Citi
Citi analyst Nigel Pittaway maintained a Hold rating on ASX (ASXFF – Research Report) today and set a price target of A$71.60. The company's shares closed last Tuesday at $45.35.
Confident Investing Starts Here:
According to TipRanks, Pittaway is a 4-star analyst with an average return of 3.6% and a 57.44% success rate. Pittaway covers the Financial sector, focusing on stocks such as Challenger , QBE Insurance Group Limited, and ASX .
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for ASX with a $42.99 average price target.
The company has a one-year high of $50.05 and a one-year low of $36.25. Currently, ASX has an average volume of 641.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Citi Increases PT on Oracle (ORCL), Keeps Neutral
Oracle Corporation (NYSE:ORCL) is one of the 10 software stocks analysts are upgrading. On June 12, Citi raised the price target on the company's stock to $196 from $186, while keeping a 'Neutral' rating. The firm believes that Oracle Corporation (NYSE:ORCL)'s Q4 2025 results are incrementally positive considering fiscal 2026 demand. That being said, the company's near-term earnings and FCF estimates have been falling. A team of IT professionals meticulously crafting a large-scale enterprise performance management system. As per Citi, Oracle Corporation (NYSE:ORCL) posted a strong Q4 2025, while it saw modest bookings growth. However, this was overshadowed by a strong fiscal 2026 sales outlook amidst accelerating cloud, remaining performance obligation, and total revenue growth, added the analyst. Oracle Corporation (NYSE:ORCL) expects its total cloud growth rate, applications plus infrastructure, to increase from 24% in FY 2025 to more than 40% in FY 2026. Notably, the Cloud Infrastructure growth rate is anticipated to increase from 50% in FY 2025 to more than 70% in FY 2026, while RPO is projected to grow over 100% in FY 2026. Also, Oracle Corporation (NYSE:ORCL) anticipates triple-digit MultiCloud revenue growth to continue in FY 2026. Ariel Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Lastly, global leader in enterprise software, Oracle Corporation (NYSE:ORCL), traded lower alongside the broader technology sector due to macroeconomic uncertainty and in particular, the near-term prospects for artificial intelligence investment (AI) spending. As a result, ORCL reported weaker than expected quarterly earnings results. Nonetheless, management expects double-digit growth for fiscal 2026 and 2027, citing significant demand for its cloud and AI capabilities. This supports our view that ORCL's positioning as the leading provider of database software and cloud-based infrastructure is entrenched, making it a key beneficiary of global demand for generative AI development.' While we acknowledge the potential of ORCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORCL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
Yahoo
5 hours ago
- Yahoo
Private companies own 33% of Yancoal Australia Ltd (ASX:YAL) shares but retail investors control 59% of the company
The considerable ownership by retail investors in Yancoal Australia indicates that they collectively have a greater say in management and business strategy A total of 25 investors have a majority stake in the company with 40% ownership Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. To get a sense of who is truly in control of Yancoal Australia Ltd (ASX:YAL), it is important to understand the ownership structure of the business. With 59% stake, retail investors possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Private companies, on the other hand, account for 33% of the company's stockholders. Let's take a closer look to see what the different types of shareholders can tell us about Yancoal Australia. Check out our latest analysis for Yancoal Australia Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Yancoal Australia already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Yancoal Australia, (below). Of course, keep in mind that there are other factors to consider, too. We note that hedge funds don't have a meaningful investment in Yancoal Australia. The company's largest shareholder is Shandong Energy Group Co., Ltd., with ownership of 24%. With 7.7% and 1.5% of the shares outstanding respectively, Cinda International HGB Investment (UK) Limited and The Vanguard Group, Inc. are the second and third largest shareholders. Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own less than 1% of Yancoal Australia Ltd. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Keep in mind that it's a big company, and the insiders own AU$44m worth of shares. The absolute value might be more important than the proportional share. It is good to see board members owning shares, but it might be worth checking if those insiders have been buying. The general public, who are usually individual investors, hold a substantial 59% stake in Yancoal Australia, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. Our data indicates that Private Companies hold 33%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company. It's always worth thinking about the different groups who own shares in a company. But to understand Yancoal Australia better, we need to consider many other factors. Take risks for example - Yancoal Australia has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
